Elixir places first DESolve drug-eluting stent in patient

Elixir Medical placed its first DESolve drug-eluting stent in a patient in Germany since gaining its CE mark last year.

Amid RNAi buzz, Arcturus touts positive preclinical results

San Diego-based Arcturus Therapeutics added some juice to the RNAi buzz this week at the J.P. Morgan Healthcare Conference with results from a preclinical study that showed a hefty knockdown of the genetic disease transthyretin-mediated amyloidosis.

'On-off' switch in disguised nanoparticles shows delivery potential

A nanoparticle with a specific code mechanism for release could allow drug-carrying vehicles to issue their payload upon contact with a specific biomarker. Now, researchers have developed a nanoparticle that uses coded DNA as this kind of "on-off" switch.

Cynapsus' sublingual strip for severe Parkinson's reduces side effects in a study

Canada-based Cynapsus has come up with the first sublingual option for the delivery of apomorphine to patients with Parkinson's disease to control their debilitating "off" episodes. This week, the company heralded results from a study comparing the thin film strip with a subcutaneous injection of the same drug, noting a reduction in side effects.

Roche's delivery method 'shuttles' Alzheimer's drugs past the blood-brain barrier

Crossing the blood-brain barrier is notoriously difficult, but overcoming that obstacle can have vast implications for the treatment of Alzheimer's, Huntington's and brain cancer. Now researchers at Roche have developed an antibody-based technique to "shuttle" large molecules into the brain, increasing exposure to the drug.

Global nanomed market, driven by brain delivery, is expected to reach $177B by 2019

Analysts predict the global market for nanotechnology in medicine, which amounted to almost $79 billion in 2012, will surpass $177 billion by 2019.

India to require all changes in delivery to be regulated as a new drug

India's health ministry is amending its rule for drug delivery systems to require any change in delivery method to undergo the full regulatory process of a new drug.

Armed with cancer drugs, white blood cells become cancer-killing sticky bombs

Like any moving target, cancer that has metastasized is notoriously difficult to treat. One of the major hurdles in cancer research is the detection of cancer cells that have spread in the body, but researchers at Cornell have developed a compound that could piggyback on white blood cells and deliver cancer-killing drugs very effectively.

Vaccine nanoparticles offer shake-and-bake field delivery

To be able to make vaccines on site simply and effectively would greatly benefit remote areas that are often hampered by both distance from the source of vaccines and the difficulty of refrigeration. And researchers at the University of Washington have developed a nanotech delivery solution that could give vaccinators a leg up in the field.

Durect, Impax tie up for a shingles patch to last 6 times as long as Lidoderm

Impax Laboratories is tapping Durect Corporation for its mid-stage transdermal patch Eladur, which is designed to ease the pain associated with shingles. For exclusive rights to the delivery tech, Impax agreed to pay up to $63 million to Durect when all is said and done.

How a single nanoparticle delivers two drugs separately to kill cancer cells

Two birds with one stone? How about two drug targets with one delivery vehicle? Researchers in North Carolina have developed a single nanoparticle capable of carrying two separate drugs to two different locations in a cancer cell. The aim is to program the delivery in such a way that maximizes the efficiency of each drug.

Gene delivery method 'hijacks' tumor blood vessels

In what could become a vast improvement to the delivery of gene therapy within the body, U.S. researchers have developed injectable DNA-carrying viruses that could eventually stop tumor growth or make chemotherapy more effective.

Belgian Cardio3 BioSciences corrals $5.5M for a stem cell delivery tech trial

Cardio3 BioSciences pulled in €4 million ($5.5 million) in regional government funding to help support U.S. commercialization of its C-Cathez catheter for delivering stem cell treatments directly into the heart.

'Walking' DNA motor on nanotube tracks could someday deliver drugs

Inspired by natural biological "motors" made of protein, researchers at Purdue University have developed a DNA-based molecule that can "walk" across the surface of nanotubes, potentially carrying nanomeds with them for the purpose of drug delivery.

Artificial cells made en masse offer insight into delivery across membrane

Biomedical engineers have developed a method to mass-produce artificial cells with dynamic membrane structures to be used in the research of new delivery techniques.

Austrian team improves RNAi 'hairpin' structures for more efficient delivery

Back in 2006, Andrew Fire and Craig Mello won the Nobel Prize in Physiology or Medicine for their discovery of RNA interference in "silencing" genes. Today, nearly a decade later, the technology is still in limbo due to difficulties delivering the genetic material to cells.

Alnylam begins a PhII trial for amyloidosis RNAi treatment

Alnylam Pharmaceuticals began a Phase II study of its RNAi drug designed to treat TTR-mediated amyloidosis, an inherited, fatal disease caused by genetic mutations.

Magnetic sperm-driven micro-robots swim to deliver drugs

To get microscopic drug carriers swimming toward a target, German researchers took a cue from some of the best swimmers in nature: sperm cells.

Rutgers team delivers RNA to weaken drug-resistant ovarian cancer

Ovarian cancer cells are known to form resistance over time to chemotherapy, limiting the effect that standard cancer drugs can have on the disease. And now, researchers at Rutgers University have developed an RNA method to attack rampant proteins causing the drug resistance, allowing chemotherapy to then take out the cells.

Sanofi's Genzyme nets FDA priority review for its oral Gaucher pill

Sanofi's Genzyme snagged a 6-month priority review from the FDA for what could become the first oral treatment for Gaucher disease, a rare genetic disorder that causes abnormal fat buildup in cells, enlarging organs in the body.